Taking the lead: ABVC BioPharma Inc (ABVC)

With 1.33 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.57 million shares. The 52-week range on ABVC shows that it touched its highest point at $1.73 and its lowest point at $0.40 during that stretch. It currently has a 1-year price target of $20.20. Beta for the stock currently stands at 0.69.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ABVC was up-trending over the past week, with a rise of 62.48%, but this was up by 39.03% over a month. Three-month performance surged to 41.22% while six-month performance rose 1.51%. The stock lost -37.67% in the past year, while it has gained 25.71% so far this year.

Float and Shares Shorts:

At present, 12.71 million ABVC shares are outstanding with a float of 11.24 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ABVC since 1 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$4.4 being high and -$4.4 being low. For ABVC, this leads to a yearly average estimate of -$4.4. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.